Form 6-K Ascendis Pharma A/S For: Sep 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ascendis Pharma (ASND) PT Raised to $179 at Jefferies
September 16, 2024 4:35 PM EDTJefferies analyst Kelly Shi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $179.00 (from $174.00) while maintaining a Buy rating.
The analyst comments "Co reported pivotal data from Navepegritide (TransCon CNP) in children w/ achondroplasia aged 2-11yo, which showed an... More
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND), PT $175
September 16, 2024 12:07 PM EDTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $175.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "ASND could be on its way to a third approved product using its long-acting TransCon technology. Today, it announced positive topline results for... More
Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs
September 16, 2024 12:06 PM EDTGoldman Sachs analyst Paul Choi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $180.00) while maintaining a Buy rating.
The analyst comments "Topline ApproaCH data indicate clear clinical benefit for TransCon CNP and competitive efficacy/safety/convenience profile; looking to detailed data and... More
Stifel on Ascendis Pharma (ASND): 'A Clear Win Following Recent Commercial Setbacks'
September 16, 2024 10:25 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $200.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "TransCon CNP succeeded in the Ph2/3 ApproaCH study in achondroplasia. On the primary endpoint of annualized growth velocity (AGV) the drug achieved a 1.49cm/yr delta vs. placebo (p... More
Citi Reiterates Buy Rating on Ascendis Pharma (ASND)
September 13, 2024 12:59 PM EDTCiti analyst David Lebowitz reiterated a Buy rating and $178.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "At the European Society for Medical Oncology (ESMO) (9/13-9/17), Ascendis will present data from the platinum-resistant ovarian cancer (PROC) cohort of its Ph1/2... More
